Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial - Tesch, H; Stoetzer, O; Decker, T (Int J Cancer, 2019)
et al.